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Abstract
Background:  Monolysocardiolipin acyltransferase (MLCL AT) catalyzes the acylation of
monolysocardiolipin to cardiolipin in mammalian tissues. We previously reported that cardiac
cardiolipin levels, MLCL AT and cardiolipin synthase activities were all elevated in rats made
hyperthyroid by thyroxine treatment. In this study, we examined if cardiac mitochondrial MLCL AT
activity was dependent upon the biosynthesis and level of cardiolipin in the heart. Rat heart
mitochondrial MLCL AT activity was determined under conditions in which the levels of cardiac
cardiolipin and cardiolipin synthase activity were either reduced or unaltered using four different
disease models in the rat. In addition, these parameters were examined in a murine model of
cardiac cell differentiation.
Results: In rats made hypothyroid by treatment with 6-n-propyl-2-thiouracil in the drinking water
for 34 days, cardiac cardiolipin content was decreased 29% (p < 0.025) and this was associated with
a 32% decrease (p < 0.025) in cardiolipin synthase and a 35% reduction (p < 0.025) in MLCL AT
activities. Streptozotocin-induced diabetes or hyperinsulinemia in rats did not affect cardiac
cardiolipin content nor MLCL AT and cardiolipin synthase activities. Finally, cardiolipin content,
MLCL AT and cardiolipin synthase activities were unaltered during murine P19 teratocarcinoma
cell differentiation into cardiac myocytes. In all models, phospholipase A2 activities were unaltered
compared with controls.
Conclusion: We propose a general model in which the expression of MLCL AT activity is
regulated in concert with the biosynthesis and level of cardiolipin in the heart.
Background
Phospholipids are important structural and functional
components of the biological membrane [1]. Structurally,
as major components of the biological membrane, they
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define compartmentalization of organelles and the pro-
tective barrier, the cell membrane, which surrounds cells.
An important class of phospholipids are the polyglycero-
phospholipids. Cardiolipin (CL), the first polyglycero-
phospholipid discovered, was isolated from beef heart by
Pangborn in 1942 [2]. In the heart, CL represents approx-
imately 12–16% of the entire cardiac phospholipid mass
and is found exclusively in mitochondria [3].
In mammalian tissues CL is required for the reconstituted
activity of a number of key mitochondrial enzymes in-
volved in cellular energy metabolism including for exam-
ple cytochrome c oxidase, carnitine palmitoyltransferase,
creatine phosphokinase, pyruvate translocator, mono-, di-
and tricarboxylate carriers, glycerol-3-phosphate dehydro-
genase, phosphate transporter, ATP/ADP translocase and
ATP synthase [4]. Under experimental conditions in
which CL was removed or digested away from these pro-
teins with phospholipases, denaturation and complete
loss in activity of many of these proteins was observed. CL
interaction with these proteins was specific since substitu-
tion with other phospholipids did not fully reconstitute
activity. The fatty acyl composition of CL also appeared to
be important for this functional reconstitution. For exam-
ple, the activity of delipidated rat liver cytochrome c oxi-
dase was reconstituted by the addition of CL [5]. The
specific activity of reconstituted cytochrome c oxidase var-
ied significantly with different fatty acyl compositions of
CL. A strong positive correlation has been established be-
tween fatty acid unsaturation of CL and antioxidant pro-
duction in cells [6]. In staurosporine-treated granulosa
cells undergoing apoptosis CL levels were reduced [7].
Peroxidation of CL induced release of cytochrome c from
mitochondria into the cytosol and this was associated
with the induction of apoptosis [8–10]. Suppression of CL
peroxidation inhibited release of cytochrome c from mi-
tochondria [11]. Thus, the activities of the enzymes that
synthesize and remodel CL play a pivotal role in main-
taining the content and molecular composition of CL and
hence may regulate a plethora of cellular processes from
energy metabolism to apoptosis.
In mammalian tissues CL is synthesized by condensation
of phosphatidylglycerol with cytidine-5'-diphosphate-
1,2-diacyl-sn-glycerol catalyzed by CL synthase [for review
see [12]]. Thyroxine treatment of rats stimulated the ex-
pression of rat liver and heart mitochondrial CL synthase
activities [13,14]. The increase in CL synthase activity ac-
counted for the elevated levels of CL observed in these or-
gans. We recently identified and characterized the activity
of monolysocardiolipin acyltransferase (MLCL AT), the
enzyme responsible for monolysocardiolipin (MLCL)
acylation to CL in mammalian tissues [15]. In another
study, we showed that thyroxine treatment of rats elevated
cardiac MLCL AT activity and postulated that MLCL AT
may be a rate-limiting enzyme for the molecular remode-
ling of CL in the heart [16]. The above studies prompted
us to examine if cardiac MLCL AT activity was linked to CL
biosynthesis and content in the heart. Our results, using
four different disease models in the rat in which the level
of cardiac CL is either reduced, elevated or unaltered,
demonstrate that this is the case. We also observe this re-
lationship in a model of murine cardiac cell differentia-
tion.
Results
Cardiac CL content, CL synthase and MLCL AT activities 
are reduced in hypothyroid rats
In previous studies we observed that cardiac MLCL AT ac-
tivity was elevated when the cardiac CL content and CL
synthase activity were elevated in hyperthyroid rats
[14,16]. We examined if cardiac CL content, CL synthase
and MLCL AT activities were reduced in hypothyroid rats.
Rats were made hypothyroid by the addition of 0.05%
PTU to their drinking water for 34 days. This protocol was
shown to produce decreased serum thyroid hormone lev-
els and result in cardiac atrophy in the rat [23]. As seen in
Table 1, in rats that received PTU there was a 48% decrease
(p < 0.025) in heart weight compared to controls. In addi-
tion, the heart to body weight ratio decreased, indicative
of cardiac atrophy. Growth failure was demonstrated by
the decreased body weights of the hypothyroid animals
compared to controls. As a further control, the activity of
an inner mitochondrial membrane marker, succinate de-
hydrogenase, was determined. Cardiac mitochondrial
succinate dehydrogenase activity was reduced 23% (p <
0.025) from 30 ± 3 µmol/min·mg to 23 ± 3 µmol/
min·mg protein in PTU-treated rats. These are document-
ed characteristics of hypothyroidism [24].
Table 1: Body weight, heart weight, heart CL content, CL syn-
thase and MLCL AT activities in normal and hypothyroid rats.
Control Hypothyroid
Heart weight (g) 1.23 ± 0.03 0.64 ± 0.04*
Body weight (g)
Before PTU treatment 206 ± 4 205 ± 4
After PTU treatment 441 ± 19 275 ± 20*
Heart weight:body weight (× 100) 0.28 ± 0.02 0.23 ± 0.03*
nmol/mg heart
CL content 6.1 ± 0.1 4.3 ± 0.4*
pmol/min·mg protein
CL synthase activity 3.1 ± 0.3 2.1 ± 0.2*
MLCL AT activity 40 ± 6 26 ± 3*
Rats were made hypothyroid by administration of 0.05% 
PTU in the drinking water for 34 days. The hearts were har-
vested, weighed and CL content, CL synthase and MLCL AT activities 
determined. Results represent the mean ± standard deviation of ten 
animals *p < 0.025.BMC Biochemistry 2002, 3  http://www.biomedcentral.com/1471-2091/3/9
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Heart mitochondrial fractions were prepared from rats
made hypothyroid by the addition of 0.05% PTU to their
drinking water for 34 days and CL content, CL synthase
and MLCL AT activities determined. We initially deter-
mined the activity of cardiac mitochondrial PA:CTP cyti-
dylyltransferase, a rate-limiting enzyme of CL
biosynthesis [21]. PA:CTP cytidylyltransferase activity was
15.1 ± 1.2 pmol/min/mg protein and unaltered (14.7 ±
1.1 pmol/min/mg protein) in cardiac mitochondrial frac-
tions prepared from hypothyroid rats. Hence, PA:CTP
cytidylyltransferase served as a control for a mitochondri-
al enzyme not affected by hypothyroidism. When com-
pared to controls, heart mitochondria prepared from
hypothyroid rats exhibited a 29% decrease (p < 0.025) in
CL content, a 32% decrease (p < 0.025) in CL synthase ac-
tivity and a 35% decrease (p < 0.025) in MLCL AT activity
(Table 1). PLA2 activity was 4.2 ± 0.7 nmol/min·mg pro-
tein and unaltered (4.0 ± 0.5 nmol/min·mg protein) in
cardiac mitochondria prepared from hypothyroid rats.
Thus, cardiac mitochondrial CL content, CL synthase and
MLCL AT activities were all reduced in hypothyroid rats.
Cardiac CL content, CL synthase and MLCL AT activities 
are unaltered in streptozotocin-induced diabetic rats and 
in hyperinsulinemic rats
Previously we showed that cardiac phosphatidylglycerol
levels were reduced in streptozotocin-induced diabetic
rats but CL synthase activity and CL content were unal-
tered [20]. We examined if streptozotocin-induced diabe-
tes in rats altered MLCL AT activity or if hyperinsulinemia
in rats altered CL synthase and MLCL AT activities in car-
diac mitochondria. Rats were made diabetic by injection
of steptozotocin or hyperinsulinemic by intraperitoneal
addition of insulin. Subsequently, the hearts were re-
moved and mitochondrial fractions prepared. Cardiac CL
synthase activities were 3.0 ± 0.5 pmol/min·mg protein
in hyperinsulinemic rats and did not differ from control
(3.1 ± 0.6 pmol/min·mg protein) non-insulin injected
animals. Cardiac CL content was 5.9 ± 0.5 nmol/mg heart
and unaltered compared to controls (6.1 ± 0.1 nmol/mg
heart). Cardiac MLCL AT activities were 38 ± 6 pmol/
min·mg protein in diabetic rats and 43 ± 9 pmol/min·mg
protein in hyperinsulinemic rats and did not differ from
controls (40 ± 6 pmol/min·mg protein saline injected
and 41 ± 9 pmol/min·mg protein non-insulin injected
animals, respectively). Thus, in streptozotocin-induced
diabetes and hyperinsulinemia, conditions in which the
CL content and CL synthase activities were unaltered,
MLCL AT activity was unaltered.
CL content, CL synthase and MLCL AT activities are unal-
tered during cardiac cell differentiation
As a distinct model, we examined if CL synthase activity
was altered in murine P19 teratocarcinoma cells induced
to undergo differentiation into cardiac myocytes. We
chose this model since differentiation of murine P19 cells
into cardiac myocytes results in an increase in phosphati-
dylethanolamine biosynthesis, phosphatidyleth-
anolamine mass and lysophosphatidylethanolamine
acyltransferase activities [17,25]. The cells were harvested
at various times, 0–8 days post DMSO addition, and
MRNA analysis of markers of cardiac cell differentiation
performed on cell lysates. GATA-4 is a member of the
GATA family of zinc finger transcription factors and is an
early marker of cardiac cell differentiation. As seen in Fig-
ure 1, GATA-4 was expressed at 4 days post DMSO addi-
tion relative to the constitutive expression of tubulin. As
expected GATA-4 expression preceded the expression of
other cardiac genes including B-natriuretic peptide (BNP),
alpha myosin heavy chain (α MHC), beta myosin heavy
chain (β MHC) and Troponin C relative to the constitutive
expression of tubulin. Thus, the P19 cells used in this
study differentiated into cardiac myocytes. As previously
shown CL content, MLCL AT and PLA2 activities were un-
altered during P19 cell differentiation into cardiac myo-
Figure 1
Expression of genes during differentiation of P19 cells
into cardiac myocytes. P19 cells were incubated with 1%
DMSO for up to 8 days. At various times, 0–8 days post
DMSO addition, cells were harvested and mRNA levels of
GATA-4, BNP, α  MHC, β  MHC, troponin C and tubulin
were determined by quantitative RT-PCR analysis.BMC Biochemistry 2002, 3  http://www.biomedcentral.com/1471-2091/3/9
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cytes [17,25]. CL synthase activity was 2.7 ± 0.5 pmol/
min·mg protein in undifferentiated and unaltered (2.8 ±
0.3 pmol/min·mg protein) in differentiated P19 cells. To-
gether, the above five models using hyper- and hypothy-
roid, diabetic and hyperinsulinemic rats and murine P19
cell differentiation into cardiac myocytes all indicate that
expression of mammalian cardiac mitochondrial MLCL
AT activity appears to be regulated in concert with the bi-
osynthesis and content of CL in the heart.
Discussion
Previous and current studies in the mammalian heart and 
liver support the hypothesis that CL content is regulated in 
concert with the level of CL synthase activity
In the CL biosynthetic pathway, PG is converted to CL by
condensation with CDP-DG catalyzed by CL synthase [3].
In vitro studies have indicated that alteration in cellular CL
levels appears to have functional consequences. For exam-
ple, reduction in the content of CL was shown to reduce
oxygen consumption in mitochondria prepared from rat
liver [26]. Thus, maintenance of the appropriate content
of CL in mammalian mitochondria is essential for proper
mitochondrial function. Thyroxine treatment of rats was
shown to stimulate the activity of rat liver mitochondrial
CL synthase 2.5-fold [13]. This elevation in rat liver mito-
chondrial CL synthase activity was suggested to account
for the elevated levels of CL observed in livers prepared
from hyperthyroid rats. In addition, CL synthase was
shown to be elevated in heart mitochondria prepared
from hyperthyroid rats and this was correlated with an in-
crease in cardiac CL content [14].
Prior to the current study, CL synthase activity had not
been determined in any model of hypothyroidism. Hy-
pothyroidism in the rat resulted in a 25% reduction in car-
diac CL synthase activity. This reduction in CL synthase
activity likely accounted for the reduced levels of cardiac
CL observed in hearts prepared from hypothyroid ani-
mals. Previous studies in the rat have indicated that hy-
pothyroidism also results in reduced CL levels in the liver
[for review see [4]]. Thus, it is reasonable to assume that
CL synthase activity would also be reduced in the liver of
hypothyroid animals. In the current study, CL synthase ac-
tivity was unaltered in diabetic and hyperinsulinemic rats
and in a model of murine cardiac cell differentiation. In
these models, the content of CL was unaltered. These data
suggest that the level of CL produced in the mammalian
heart is regulated in concert with the level of CL synthase
activity.
Previous and current studies in the heart support the hy-
pothesis that cardiac MLCL AT activity may be regulated 
in concert with CL content and CL synthase activity
The data presented in this paper are entirely consistent
with the conclusion that the expression of MLCL AT activ-
ity in the heart is regulated in concert with the biosynthe-
sis and content of cardiac CL. Previously, we
demonstrated that thyroxine-treatment of rats resulted in
an increase in cardiac CL content, CL synthase and MLCL
AT activities [14,16]. In the present study rats made hy-
pothyroid with PTU in the drinking water had reduced
cardiac CL content, CL synthase and MLCL AT activities.
In contrast, in streptozotocin-induced diabetes and hyper-
insulinemia, pathological conditions in which cardiac mi-
tochondial CL content and CL synthase were unaltered
[20], MLCL AT activities were unaltered. In addition, CL
content, CL synthase and MLCL AT activities were unal-
tered during cardiac cell differentiation. It is reasonable to
propose that when the rate of synthesis and level of CL is
either reduced or elevated expression of the activities of
the enzymes that remodel CL should be correspondingly
reduced or elevated. The activity of cardiac mitochondrial
PLA2 was high (100-fold) relative to cardiac mitochondri-
al MLCL AT activity and was unaltered in all models exam-
ined [20,25]. Since MLCL AT activity was either increased
or decreased under conditions in which elevated or re-
duced CL remodelling was required, i.e. elevated or re-
duced CL synthesis, it is possible that MLCL AT may be
rate-limiting for MLCL acylation to CL in the mammalian
heart. However, it should be considered that other factors
such as the intra-mitochondrial level of MLCL may be
limiting for the acylation of MLCL to CL.
Table 2: Summary of mammalian cardiac mitochondrial MLCL AT activities, CL synthase activities and CL content in various cardiac 
models.
CL content CL Synthase Activity MLCL AT Activity References
Hyperthyroidism increased increased increased [14,16]
Hypothyroidism decreased decreased decreased [this paper]
STZ-induced diabetes  unaltered unaltered unaltered [[20], this paper]
Hyperinsulinemia unaltered unaltered unaltered [this paper]
Murine P19 cell differentiation into cardiac myocytes unaltered unaltered unaltered [[17,25], this paper]BMC Biochemistry 2002, 3  http://www.biomedcentral.com/1471-2091/3/9
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Conclusions
A summary of our findings is presented in Table 2. In
hyperthyroidism, when cardiac CL synthase activity and
CL content are elevated an increase in MLCL AT activity is
observed. In hypothyroidism, when cardiac CL synthase
activity and CL content are reduced a decrease in MLCL AT
activity is observed. Finally, when cardiac CL synthase ac-
tivity and CL content are unaltered in streptozotocin-in-
duced diabetes, hyperinsulinemia and murine P19 cell
differentiation into cardiac myocytes, MLCL AT activity is
unaltered. Thus, expression of MLCL AT activity is regulat-
ed in concert with the biosynthesis and content of cardiac
CL.
Materials and Methods
Male Sprague Dawley rats (125–175 g) were used
throughout the study and were housed in a temperature
and light controlled room. They were maintained on Pu-
rina rat chow and tap water ad libitium. Treatment of an-
imals conformed to the Guidelines of the Canadian
Council on Animal Care. Rats were made hypothyroid by
administration of (0.5% w/v) 6-n-propyl-2-thiouracil
(PTU) in their drinking water for 34 days. Rats were made
diabetic by injection of 60 mg/Kg steptozotocin. Hyperg-
lycemia was confirmed 24 h later by urine and blood glu-
cose analysis. Rats were made hyperinsulinemic by
intraperitoneal addition of 3 units/day of insulin for 28
days. Murine P19 teratocarcinoma cells were kindly pro-
vided by Dr. Mona Nemer, Institute of Cardiovascular Re-
search, University of Montreal, Montreal, Quebec,
Canada. [1-14C]Linoleoyl-Coenzyme A was obtained
from American Radiochemical Co., St. Louis MO. All oth-
er radiochemicals were obtained from Dupont, Winnipeg,
Canada. MLCL was obtained from Avanti Polar Lipids, Al-
abaster, AL. Thin-layer chromatography (Silica gel 60,
0.25 mm thickness) plates were obtained from BDH, To-
ronto, Canada. Cell culture and reagents were products of
Canadian Life Technologies (GIBCO) Burlington, On-
tario, Canada. Ecolite scintillant was obtained from ICN
Biochemicals, Costa Mesa, CA.. Lipids standards were ob-
tained from Serdary Research Laboratories, Englewood
Cliffs, NJ., USA. All other biochemicals were of analytical
grade and obtained from either Fisher Scientific, Edmon-
ton, Canada, Sigma Chemical Co., St. Louis, MO. or Can-
Lab Division of Baxter Co. Winnipeg, Canada.
The protocol for differentiation and culturing of murine
P19 teratocarcinoma cells into cardiac myocytes was per-
formed as described [17]. P19 cells (5 ×  105 cells/ml) were
placed into 60 mm bacterial dishes, 1% dimethylsulfox-
ide (DMSO) was added and incubation continued for 48
h. The cells began to aggregate at this point. Cells were
then transferred to a 100 mm bacterial dish and 1%
DMSO was added for another 48 h. The cells in these 100
mm bacterial dishes differentiated into the cardiac cell lin-
eage within eight days. At various days (0–8) post DMSO
addition cells were harvested and mRNA expression of
GATA-4, BNP, α MHC, β MHC, troponin C and tubulin
were determined using quantitative RT-PCR analysis as
described [18].
A 10% homogenate from rat hearts or P19 cells was pre-
pared in buffer (0.25 M sucrose, 0.145 M NaCl, 10 mM
Tris-HCl, pH 7.4) and centrifuged for 10 min at 600 ×  g
(Beckman J2-H with JA-20 rotor). The resulting pellet was
washed once, resuspended in 5 ml buffer by 15 strokes of
a hand-held Dounce (tight fitting) tissue grinder and des-
ignated the crude nuclear fraction. The supernatant from
the first centrifugation was centrifuged at 10,000 ×  g for 10
min. The resulting pellet was resuspended in 1.5 ml buffer
as described above and used as the source of mitochondri-
al fraction for enzyme assays. Protein in this fraction was
determined by the method of Bradford [19]. Phospholi-
pase A2 (PLA2) was determined as described using phos-
phatidyl [14C]glycerol as substrate [20]. CL synthase and
phosphatidic acid (PA):CTP cytidylyltransferase activities
were determined as described [21]. MLCL AT activities
were determined as described [15]. Mitochondrial frac-
tions (50 µg) were incubated for 30 min at 25°C in 50 mM
Tris-HCL, pH 8.0, 33 µM [1-14C]linoleoyl-Coenzyme A
(68,700 dpm/nmol), 0.3 mM MLCL in a final volume of
0.35 ml. The reaction was initiated by the addition of [1-
14C]linoleoyl-Coenzyme A substrate and terminated by
addition of 3 ml of chloroform:methanol (2:1, by vol).
0.8 ml of KCL was added to facilitate phase separation.
The aqueous phase was removed and the organic phase
dried under nitrogen and resuspended in 25 µl of chloro-
form:methanol (2:1, by vol). A 20 µl aliquot was placed
on a thin layer plate and CL was separated from other
phospholipids in a solvent system containing chloro-
form:hexane:methanol:acetic acid (50:30:10:5, by vol).
The silica gel corresponding to CL was removed and
placed in plastic scintillation vials with 5 ml of aqueous
counting scintillant. Radioactivity incorporated into CL
was determined approximately 24 h later using a liquid
scintillation counter. CL content was determined as de-
scribed [21]. Mitochondrial succinate dehydrogenase ac-
tivity was determined as described [22]. Students t-test
was used for the determination of statistical significance.
The level of significance was defined as p < 0.025.
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